Study Evaluating the Safety and Efficacy of Onartuzumab (Metmab) And/Or Bevacizumab in Combination With Paclitaxel in Patients With Metastatic, Triple Negative Breast Cancer

Inclusion Criteria:

- Women age >/= 18 years

- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

- Histologically confirmed ER-, PR-, and HER2-negative (triple-negative) adenocarcinoma
of the breast

- Confirmed availability of tumor tissue

Exclusion Criteria:

- Prior therapy with two or more regimens for metastatic breast cancer

- Any systemic anti-cancer therapy within 3 weeks prior to Day 1 of Cycle 1

- Major surgical procedure, open biopsy, or significant traumatic injury within 30 days
prior to Day 1 of Cycle 1

- Prior therapy with a taxane for metastatic breast cancer

- Prior therapy with bevacizumab, sorafenib, sunitinib, or other putative VEGF
pathway-targeted therapy following diagnosis of breast cancer

- Prior therapy with hormones and/or trastuzumab

- Inadequate hematology, renal, or hepatic organ function

Bevacizumab exclusion criteria

- Uncontrolled hypertension (systolic pressure > 150 mmHg and/or diastolic pressure >
100 mmHg), with or without anti-hypertensive medication

- Evidence of bleeding diathesis or coagulopathy